Dingell, Stupak mull FDA inspection law

U.S. Reps. John Dingell, D-Mich., and Bart Stupak, D-Mich., are pondering tougher laws after the FDA failed to follow its own guidelines on the inspection of foreign drug plants. Stupak said he will look into legislation that makes it illegal to distribute a drug in the U.S. from a facility that has not undergone FDA inspection, in light of the agency's failure to inspect a Chinese plant that makes the active ingredient in Baxter's blood thinner heparin.

View Full Article in:

Boston Globe (tiered subscription model), The · Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA